Evidence map›Paper›PMID 28377488›Full record

ArticleMolecular cancer therapeutics2017

U1 Adaptors Suppress the

Ashley T Tsang, Crissy Dudgeon, Lan Yi, Xin Yu, Rafal Goraczniak, Kristen Donohue, Samuel Kogan, Mark A Brenneman, Eric S Ho, Samuel I Gunderson and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Tissue distribution pharmacokinetics of intrathecal U1 adaptor oligonucleotide in mice.Current research in pharmacology and drug discovery · 2025
    Article
  4. Article
  5. Article
  6. Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy.Frontiers in cell and developmental biology · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ashley T TsangDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Crissy DudgeonDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Lan YiRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Xin YuDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Rafal GoraczniakSilagene Inc., Hillsborough, New Jersey.
Kristen DonohueDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Samuel KoganDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Mark A BrennemanSilagene Inc., Hillsborough, New Jersey.
Eric S HoDepartment of Biology, Lafayette College, Easton, Pennsylvania.
Samuel I GundersonSilagene Inc., Hillsborough, New Jersey.
Darren R CarpizoDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey. carpizdr@cinj.rutgers.edu.
Rutgers, The State University of New Jersey · USSilaGene (United States) · USJohnson University · USLafayette College · US

Funding

Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancerDrugsR01CA200800 · NCI · UNIVERSITY OF ROCHESTER · PI CARPIZO, DARREN RICHARD · 2016 to 2020
$1.9M
Exploration of a Mutant p53 Reactivating CompoundK08CA172676 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI CARPIZO, DARREN RICHARD · 2013 to 2017
$745k
Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic CancerR21CA191622 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI CARPIZO, DARREN RICHARD, GUNDERSON, SAMUEL I · 2015 to 2016
$359k
NCI NIH HHS K08 CA172676NCI NIH HHS R01 CA200800NCI NIH HHS R21 CA191622
6 · The paper itself

Abstract

Targeting KRAS and MYC has been a tremendous challenge in cancer drug development. Genetic studies in mouse models have validated the efficacy of silencing expression of both KRAS and MYC in mutant KRAS-driven tumors. We investigated the therapeutic potential of a new oligonucleotide-mediated gene silencing technology (U1 Adaptor) targeting KRAS and MYC in pancreatic cancer. Nanoparticles in complex with anti-KRAS U1 Adaptors (U1-KRAS) showed remarkable inhibition of KRAS in different human pancreatic cancer cell lines

Indexed as

OncogenesXenograft Model Antitumor AssaysAnimalsCell Line, TumorCell ProliferationFemaleHumansMice, NudeMutationOligonucleotidesPancreatic NeoplasmsPeptidesProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Reproducibility of ResultsKRAS protein, humanOligonucleotidesPeptidesProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)

Identifiers

PMID28377488
PMCPMC5544574
OpenAlexW2604884404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.